Pharmaceutical - Antibiotics and Infectious diseases

Filter

Popular Filters

26 to 50 of 216 results

FDA approves Durata’s Dalvance to treat skin infections

26-05-2014

The US Food and Drug Administration last Friday approved Durata Therapeutics’ Dalvance (dalbavancin),…

Antibiotics and Infectious diseasesDalvanceDurata TherapeuticsPharmaceuticalRegulationUSA

New data shows Astellas’ fidaxomicin is effective as first-line treatment for Clostridium difficile infection

New data shows Astellas’ fidaxomicin is effective as first-line treatment for Clostridium difficile infection

14-05-2014

The European subsidiary of Japanese drug major Astellas Pharma has released data demonstrating that fidaxomicin…

Antibiotics and Infectious diseasesAstellas PharmaBacteriaDifficile infectionEuropefidaxomicinHealth Medical PharmaMedicineMicrobiologyPharmaceuticalResearch

Antibiotic crisis needs united global response, say UK experts

12-05-2014

Growing resistance to antibiotics and other drugs demands a coordinated global response on the same scale…

Antibiotics and Infectious diseasesGlobalHealthcarePharmaceuticalResearch

Antibiotic resistance is a serious public health threat according to WHO global report

Antibiotic resistance is a serious public health threat according to WHO global report

01-05-2014

Resistance of antibiotics is a serious threat happening now around the world, according to The World…

Antibiotics and Infectious diseasesGlobalHealthcarePharmaceutical

Otsuka wins EU approval for Deltyba in MDR-TB

30-04-2014

Japanese drugmaker Otsuka Pharmaceutical says that the European Commission has granted a marketing authorization…

Antibiotics and Infectious diseasesDeltybaEuropeOtsukaPharmaceuticalRegulation

Astellas settles with US DoJ over Mycamine marketing

Astellas settles with US DoJ over Mycamine marketing

17-04-2014

The US subsidiary of Japanese drug major Astellas Pharma will pay $7.3 million to resolve allegations…

Antibiotics and Infectious diseasesAstellas PharmaLegalMarkets & MarketingMycamineNorth AmericaPharmaceuticalUSA

Joint purchasing of vaccines and medicines becomes a reality in the EU

Joint purchasing of vaccines and medicines becomes a reality in the EU

10-04-2014

The European Commission today approved a Joint Procurement Agreement, which will enable all European…

Antibiotics and Infectious diseasesEuropeFinancialMarkets & MarketingPharmaceuticalVaccines

Tamiflu use called into question by UK report

Tamiflu use called into question by UK report

10-04-2014

The UK government and health policy decision makers are being called upon to review the guidance on the…

Antibiotics and Infectious diseasesChemistryDavid ToveyGlaxoSmithKlineHealthcareMajorPharmaceuticalRelenzaResearchRocheTamifluThe British Medical JournalUKUK government

Promising future for Cubist's Sivextro in anti-MRSA sector

04-04-2014

Following its launch, Cubist Pharmaceutical’s second generation oxazolidinone Sivextro Sivextro will…

Antibiotics and Infectious diseasesCubist PharmaceuticalsDalvanceDurata TherapeuticsMarkets & MarketingoritavancinPharmaceuticalSivextroThe Medicines Company

Global Fund taps pharmaceutical expertise in China

02-04-2014

The Global Fund is deepening its partnership with China by tapping the expertise of Chinese pharmaceutical…

Anti-viralsAntibiotics and Infectious diseasesChinaGlobalMarkets & MarketingPharmaceuticalProductionRegulation

Unanimous FDA advisory panel backing for Cubist’s Sivextro

Unanimous FDA advisory panel backing for Cubist’s Sivextro

02-04-2014

The US Food and Drug Administration’s Anti-Infective Drugs Advisory Committee on Monday voted unanimously…

Antibiotics and Infectious diseasesCubist PharmaceuticalsNorth AmericaPharmaceuticalRegulationSivextrotedizolidUSA

FDA advisory unanimously recommends Durata’s Dalvance

FDA advisory unanimously recommends Durata’s Dalvance

01-04-2014

The US Food and Drug Anti-Infective Drugs Advisory Committee voted 12 to 0 that Durata Therapeutics’…

Antibiotics and Infectious diseasesDalvanceDermatologicalsDurata TherapeuticsNorth AmericaPharmaceuticalRegulationUSA

Next-generation therapeutics for infectious diseases conquer the global spotlight

25-03-2014

The available antivirals for commonly occurring infections such as respiratory syncytial virus (RSV)…

Antibiotics and Infectious diseasesPharmaceuticalResearch

Medimetriks licenses ozenoxacin, a novel antibacterial, from Ferrer

24-03-2014

US specialty drug firm Medimetriks Pharmaceuticals has entered into a licensing agreement with Ferrer,…

Antibiotics and Infectious diseasesFerrer InternacionalLicensingMedimetriks PharmaceuticalsNorth AmericaOzenoxacinPharmaceuticalUSA

India urged to take action on unregulated tuberculosis drug sales

23-03-2014

Although cases of tuberculosis are dropping in Europe, as is the incidence in the USA, an extremely slower…

Antibiotics and Infectious diseasesAsia-PacificHealthcareIndiaPharmaceuticalResearch

Huge disparities in antibiotic consumption across European region, new report shows

Huge disparities in antibiotic consumption across European region, new report shows

20-03-2014

There is an almost fourfold difference between the lowest and the highest antibiotic users among 42 countries…

Antibiotics and Infectious diseasesEuropeMarkets & MarketingPharmaceutical

Incidence of TB down in Europe but multidrug-resistance continues

Incidence of TB down in Europe but multidrug-resistance continues

19-03-2014

Across the 53 countries of the World Health Organization European Region, an estimated 353 000 patients…

Antibiotics and Infectious diseasesEuropeHealthcarePharmaceutical

Clinigen plans to launch Vibativ after lifting of EU marketing authorization suspension

Clinigen plans to launch Vibativ after lifting of EU marketing authorization suspension

18-03-2014

UK specialty pharma company the Clinigen Group today announced that the European Commission has ratified…

Antibiotics and Infectious diseasesClinigen GroupEuropeMarkets & MarketingPharmaceuticalRegulationTelavancin for InjectionUKVibativ

High incidence and inadequate treatments boost prospects of HIV, Chagas, Dengue and influenza H1N1 drugs in Latin America

High incidence and inadequate treatments boost prospects of HIV, Chagas, Dengue and influenza H1N1 drugs in Latin America

17-03-2014

The high incidence of human immunodeficiency virus (HIV), Chagas, dengue and influenza H1N1, as well…

Anti-viralsAntibiotics and Infectious diseasesGenericsMarkets & MarketingPharmaceuticalSouth America

Janssen’s Sirturo gets conditional EU approval for multi-resistant TB

Janssen’s Sirturo gets conditional EU approval for multi-resistant TB

10-03-2014

US health care giant Johnson & Johnson’s European subsidiary Janssen-Cilag has been granted conditional…

Antibiotics and Infectious diseasesEuropeJanssen-CilagJohnson & JohnsonPharmaceuticalRegulationSirturo

Severe diarrheal illness in children linked to antibiotics prescribed in US doctor’s offices; study

10-03-2014

The majority of pediatric Clostridium difficile infections, which are bacterial infections that cause…

Antibiotics and Infectious diseasesHealthcareNorth AmericaPharmaceutical

FDA approves label changes for Doribax to reflect risks

10-03-2014

The US Food and Drug Administration has approved label changes for the antibacterial Doribax (doripenem)…

Antibiotics and Infectious diseasesDoribaxNorth AmericaPharmaceuticalRegulationShionogiUSA

AbbVie presents positive Phase III results in patients with chronic hepatitis C

AbbVie presents positive Phase III results in patients with chronic hepatitis C

04-03-2014

The first detailed results from US drugmaker AbbVie’s pivotal Phase III study, PEARL-III, have been…

AbbVieAntibiotics and Infectious diseasesPharmaceuticalResearchUSA

Astellas amends license deal for isavuconazole with Basilea

01-03-2014

Japanese drug major Astellas Pharma has amended the license, co-development and co-promotion agreement…

Antibiotics and Infectious diseasesAstellas PharmaBasilea PharmaceuticaCanadaisavuconazoleLicensingNorth AmericaPharmaceuticalUSA

26 to 50 of 216 results

Back to top